GlassScriptPhysician profile
Douglas A Koppel
NPI 1376616409
$75,075.71
in general payments reported to CMS, 2019-2025
39 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,928 · 2020: $1,907 · 2021: $2,795 · 2022: $2,481 · 2023: $20K · 2024: $11K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $18K · Food and Beverage: $9,507 · Travel and Lodging: $6,183 · Education: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,700.00 |
| Consulting Fee | $18,087.50 |
| Food and Beverage | $9,506.51 |
| Travel and Lodging | $6,182.90 |
| Education | $487.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $25,445.75 | 2019-2024 | Aklief |
| Arcutis Biotherapeutics, INC. | $21,637.32 | 2023-2025 | Zoryve |
| Kowa Pharmaceuticals America, INC. | $8,244.68 | 2025 | Zoryve |
| Janssen Biotech, INC. | $3,935.49 | 2019-2025 | Tremfya |
| Abbvie INC. | $2,026.61 | 2019-2025 | |
| Genzyme Corporation | $1,653.15 | 2019-2025 | |
| Journey Medical Corporation | $1,557.73 | 2019-2025 | |
| Medimetriks Pharmaceuticals, INC. | $1,334.41 | 2019-2025 | Neo-Synalar |
| Mayne Pharma Commercial LLC | $1,284.25 | 2019-2025 | |
| Pfizer INC. | $1,151.82 | 2019-2025 | |
| Lilly USA, LLC | $1,127.95 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $938.03 | 2019-2025 | Bimzelx |
| Amgen INC. | $635.03 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $578.09 | 2020-2025 | Dupixent |
| Epi Health, LLC | $476.57 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $413.81 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $373.52 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $354.02 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $310.90 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $285.55 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $231.76 | 2019-2023 | Arazlo, Duobrii |
| Almirall LLC | $181.99 | 2020-2025 | Seysara, Klisyri |
| Sanofi-Aventis U.S. LLC | $159.23 | 2019-2021 | |
| Genentech USA, INC. | $115.89 | 2019-2021 | |
| Revance Therapeutics, INC. | $98.61 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.45 | 2022-2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $82.40 | 2020-2021 | |
| Organon LLC | $54.37 | 2025 | Vtama |
| Botanix Sb INC | $42.92 | 2025 | Sofdra |
| Incyte Corporation | $38.93 | 2021-2025 | Opzelura |
| Dermira, INC. | $38.48 | 2020-2021 | |
| Celgene Corporation | $31.63 | 2019 | |
| Allergan, INC. | $27.18 | 2019-2021 | |
| Hill Dermaceuticals, INC. | $26.16 | 2023 | Tolak |
| Organogenesis INC. | $21.90 | 2021 | |
| Promius Pharma LLC | $20.92 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.87 | 2023 | Ycanth |
| Biofrontera INC. | $17.84 | 2020 | |
| Cipher Pharmaceuticals US LLC | $17.50 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Koppel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.